What changed today in Metabolic: 20 trial updates, 9 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Obesity drug pipeline
Investigational obesity and metabolic medicines in clinical development — multi-agonists, amylin combinations, muscle-preserving agents and oral therapies.
Building
- Editorial attention
- Building
- Tracked this week
- 4
- Sources this week
- 3
- Last activity
- 5 hrs ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Obesity drug pipeline at a glance
- About this topic
- Investigational obesity and metabolic medicines in clinical development — multi-agonists, amylin combinations, muscle-preserving agents and oral therapies.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished… (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Sep 29, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
- 1 NPHLA briefing on this topic
What’s the latest on Obesity drug pipeline?
1 totalWhat do the official records show?
Primary sources and peer-reviewed research- New trial registered: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished… (opens the source in a new tab)
Phase 3, Boehringer Ingelheim. Conditions: Obesity. Interventions: Survodutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver… (opens the source in a new tab)
Phase 3, Boehringer Ingelheim. Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide. Investigational: trial-stage therapies are not approved for the use studied.
Which clinical trials are being tracked?
All trials- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
Peking University People's Hospital. Conditions: Obesity; Chronic Kidney Disease; Albuminuria. Investigational — not approved for the use studied.
- DEFINE: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
Cambridge University Hospitals NHS Foundation Trust. Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus. Investigational — not approved for the use studied.
- TRPTI Metabolic and GLP-1 Pharmacodynamic Study
RDC Clinical Pty Ltd. Conditions: Overweight , Obesity. Investigational — not approved for the use studied.
- EryAdo: Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents
University Hospital, Basel, Switzerland. Conditions: Insulin Resistance; Glucose Tolerance; Body Composition; Gastrointestinal Tolerance; Thrombocyte Aggregation; Blood p…. Investigational — not approved for the use studied.
- STAY-LEAN: Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
The Cleveland Clinic. Conditions: Obesity. Investigational — not approved for the use studied.